Kadimastem develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as amyotrophic lateral sclerosis (ALS) and diabetes.

LifeMap Sciences develops and commercializes next-generation sequencing (NGS) analysis solutions. The company's core technology, the GeneCards Suite Knowledgebase, provides a tool to improve biomedical research and healthcare.

IDEA Bio-Medical is a commercial-stage company specializing in solutions for biological cell-imaging research, drug-discovery automation, and diagnostics.

Immunity Pharma (IPL) develops therapies for neurodegenerative diseases with an initial focus on amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

miCure Therapeutics is a biotechnology company leveraging microRNA-based therapeutics and diagnostics for neurodegenerative and psychiatric disorders.

Neurogenic is a clinical-stage diagnostics company advancing the development of a novel ELISA-based immunoassay to detect pathological Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients to facilitate the diagnosis of early-onset schizophrenia.

SynVaccine has developed a CAD/CAM platform for designing and fabricating designer viruses for biotechnology.

BiomX is a microbiome company developing customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and colorectalcancer (CRC), as well as bacteria that affect the appearance of the skin.